Gotham Asset Management LLC Purchases 144,475 Shares of Illumina, Inc. $ILMN

Key Points

• Gotham Asset Management increased its stake in Illumina by 97.5%, buying 144,475 shares to hold 292,688 shares worth about $27.8 million (≈0.19% of the company).
• Illumina beat last quarter's estimates with $1.35 EPS vs. $1.26 expected and $1.16B revenue vs. $1.10B, and set FY2026 guidance of $5.05–$5.20 EPS.
• Institutional ownership is high at 89.42% while insiders own 0.17%, and analysts' consensus is a Hold with an average price target of $129.69 (6 Buy / 10 Hold / 2 Sell).

Gotham Asset Management LLC raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 97.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 292,688 shares of the life sciences company's stock after purchasing an additional 144,475 shares during the quarter. Gotham Asset Management LLC owned 0.19% of Illumina worth $27,797,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Quent Capital LLC bought a new stake in Illumina in the 3rd quarter valued at approximately $29,000. Aster Capital Management DIFC Ltd acquired a new position in Illumina during the 3rd quarter worth approximately $33,000. Mather Group LLC. bought a new position in shares of Illumina during the 3rd quarter worth approximately $46,000. Evelyn Partners Investment Management LLP grew its stake in shares of Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company's stock worth $49,000 after acquiring an additional 542 shares in the last quarter. Finally, SJS Investment Consulting Inc. raised its holdings in shares of Illumina by 13,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company's stock valued at $51,000 after purchasing an additional 529 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Transactions at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the business's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.17% of the stock is owned by company insiders.

Illumina Stock Up 0.3%

Shares of ILMN opened at $119.28 on Tuesday. The firm has a market cap of $18.24 billion, a P/E ratio of 21.89, a price-to-earnings-growth ratio of 2.28 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The firm's 50-day simple moving average is $132.71 and its 200 day simple moving average is $120.24.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the business posted $0.95 earnings per share. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Zacks Research lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, December 31st. JPMorgan Chase & Co. lowered their price target on shares of Illumina from $130.00 to $120.00 and set a "neutral" rating on the stock in a research note on Friday, February 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Illumina in a research report on Monday, December 29th. TD Cowen restated a "hold" rating on shares of Illumina in a research note on Wednesday, January 7th. Finally, Barclays raised their price objective on Illumina from $100.00 to $110.00 and gave the company an "underweight" rating in a report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $129.69.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.